CancerDrs

Cervical Cancer clinical trials in Arizona

30 actively recruiting cervical cancer trials at 11 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Arizona:
  • Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
  • Arizona Center for Cancer Care-Peoria — Peoria, Arizona
  • Arizona Center for Cancer Care - Biltmore — Phoenix, Arizona
  • Arizona Center for Cancer Care - Phoenix — Phoenix, Arizona
  • Arizona Center for Cancer Care - Osborn — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Arizona:
  • Research Site — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Arizona:
  • Ironwood Cancer and Research Center — Chandler, Arizona
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…

Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in Arizona:
  • Mayo Clinic Hospital — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Arizona:
  • Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
  • Arizona Center for Cancer Care-Peoria — Peoria, Arizona
  • Arizona Center for Cancer Care - Phoenix — Phoenix, Arizona
  • Arizona Center for Cancer Care - Scottsdale — Scottsdale, Arizona
  • Arizona Center for Cancer Care-Surprise — Surprise, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Arizona:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Arizona:
  • Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Arizona:
  • Mayo Clinic Comprehensive Cancer Center — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Arizona:
  • Mayo Foundation for Medical Education and Research - Mayo Cl — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ra…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06445972
Sites in Arizona:
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927) — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04870762
Sites in Arizona:
  • Banner Health/Banner Research — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …

Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Arizona:
  • HonorHealth Research Institute — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…

Sponsor: University of Arizona
NCT ID: NCT06814496
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard tr…

Sponsor: Mayo Clinic
NCT ID: NCT05541016
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing …

Sponsor: University of Arizona
NCT ID: NCT07407582
Sites in Arizona:
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Arizona:
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…

Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in Arizona:
  • University of Arizona Cancer Center - Tucson /ID# 262698 — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…

Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Arizona:
  • HonorHealth Cancer Care - Biltmore - AZCCC Imaging — Phoenix, Arizona
  • HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy — Phoenix, Arizona
  • HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore — Phoenix, Arizona
  • Sonora Quest Laboratories, LLC — Phoenix, Arizona
  • South West Medical Imaging (SMIL) — Phoenix, Arizona
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Arizona:
  • Research Site — Bullhead City, Arizona
  • Research Site — Casa Grande, Arizona
View on ClinicalTrials.gov →

Showing 25 of 30 trials with sites in Arizona. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01